Last reviewed · How we verify

Ondansetron Oral Soluble Pellicles

The First Affiliated Hospital of Xinxiang Medical College · Phase 3 active Small molecule

Ondansetron Oral Soluble Pellicles is a Serotonin 5-HT3 receptor antagonist Small molecule drug developed by The First Affiliated Hospital of Xinxiang Medical College. It is currently in Phase 3 development for Prevention of nausea and vomiting caused by cancer chemotherapy, Prevention of nausea and vomiting caused by radiation therapy. Also known as: Aiqisu.

Ondansetron works by blocking serotonin receptors in the body, which helps to reduce nausea and vomiting.

Ondansetron works by blocking serotonin receptors in the body, which helps to reduce nausea and vomiting. Used for Prevention of nausea and vomiting caused by cancer chemotherapy, Prevention of nausea and vomiting caused by radiation therapy.

At a glance

Generic nameOndansetron Oral Soluble Pellicles
Also known asAiqisu
SponsorThe First Affiliated Hospital of Xinxiang Medical College
Drug classSerotonin 5-HT3 receptor antagonist
Target5-HT3 receptor
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

This is achieved by selectively antagonizing the 5-HT3 receptor, a subtype of serotonin receptor found in the gastrointestinal tract and the central nervous system. By blocking these receptors, ondansetron reduces the vomiting reflex and alleviates nausea.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Ondansetron Oral Soluble Pellicles

What is Ondansetron Oral Soluble Pellicles?

Ondansetron Oral Soluble Pellicles is a Serotonin 5-HT3 receptor antagonist drug developed by The First Affiliated Hospital of Xinxiang Medical College, indicated for Prevention of nausea and vomiting caused by cancer chemotherapy, Prevention of nausea and vomiting caused by radiation therapy.

How does Ondansetron Oral Soluble Pellicles work?

Ondansetron works by blocking serotonin receptors in the body, which helps to reduce nausea and vomiting.

What is Ondansetron Oral Soluble Pellicles used for?

Ondansetron Oral Soluble Pellicles is indicated for Prevention of nausea and vomiting caused by cancer chemotherapy, Prevention of nausea and vomiting caused by radiation therapy.

Who makes Ondansetron Oral Soluble Pellicles?

Ondansetron Oral Soluble Pellicles is developed by The First Affiliated Hospital of Xinxiang Medical College (see full The First Affiliated Hospital of Xinxiang Medical College pipeline at /company/the-first-affiliated-hospital-of-xinxiang-medical-college).

Is Ondansetron Oral Soluble Pellicles also known as anything else?

Ondansetron Oral Soluble Pellicles is also known as Aiqisu.

What drug class is Ondansetron Oral Soluble Pellicles in?

Ondansetron Oral Soluble Pellicles belongs to the Serotonin 5-HT3 receptor antagonist class. See all Serotonin 5-HT3 receptor antagonist drugs at /class/serotonin-5-ht3-receptor-antagonist.

What development phase is Ondansetron Oral Soluble Pellicles in?

Ondansetron Oral Soluble Pellicles is in Phase 3.

What are the side effects of Ondansetron Oral Soluble Pellicles?

Common side effects of Ondansetron Oral Soluble Pellicles include Headache, Dizziness, Constipation, Diarrhea, Fatigue.

What does Ondansetron Oral Soluble Pellicles target?

Ondansetron Oral Soluble Pellicles targets 5-HT3 receptor and is a Serotonin 5-HT3 receptor antagonist.

Related